isavuconazole and repaglinide

isavuconazole has been researched along with repaglinide* in 1 studies

Trials

1 trial(s) available for isavuconazole and repaglinide

ArticleYear
Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.
    Clinical pharmacology in drug development, 2017, Volume: 6, Issue:1

    This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n = 24), and methadone (CYP2B6/CYP2C19/CYP3A4; 10 mg; n = 23). Compared with each drug alone, coadministration with isavuconazole changed the area under the concentration-time curves (AUC

    Topics: Adult; Area Under Curve; Bupropion; Caffeine; Carbamates; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Methadone; Middle Aged; Nitriles; Piperidines; Pyridines; Triazoles; Young Adult

2017